
The Wall Street Journal @WSJ
Carl Icahn is preparing a proxy fight at Illumina, arguing the biotechnology company cost its shareholders roughly $50 billion by plowing ahead with a risky acquisition despite opposition from regulators https://t.co/SgiUI4BIz2 — PolitiTweet.org